FDA's approval of new cannabis-based drug will pave the way for similar meds, says CEO

Monday's FDA approval of GW Pharmaceuticals' new epilepsy drug will lead to other treatments derived from cannabis, says CEO Justin Gover. The medication is being evaluated by the DEA, which must also approve it before it can be sold. On Monday, the Food and Drug Administration approved the company's new epilepsy drug , Epidiolex, the first cannabis-based drug the U.S. regulator has approved.